Azurity Pharmaceuticals
Manufacturing · Massachusetts, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
8 Cabot Rd Ste 2000, Woburn, Massachuset...Phone Number
(800) 461-7449Website
www.azurity.comRevenue
$270.1 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
6
8
1
2
2
2
About Azurity Pharmaceuticals
Azurity Pharmaceuticals is a privately held biopharmaceutical company focused on developing and delivering innovative, high-quality medicines for underserved patients. With a diverse portfolio across multiple therapeutic areas and dosage forms, the company leverages advanced commercial strategies, data, and digital tools to enhance reach and engagement, aiming to improve patient outcomes and address unmet medical needs globally.Explore more
Azurity Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Azurity Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Azurity Pharmaceuticals
Website visits: Recent activity has been detected on your website
Click to see if Azurity Pharmaceuticals had a recent Job posting/layoffs
Check out if Azurity Pharmaceuticals is spiking on competitors!
Earning: See what the market has to say on Azurity Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Azurity Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Azurity Pharmaceuticals has new funding data
Product Launch: Get notified when Azurity Pharmaceuticals launches new products
Check if Azurity Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Azurity Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Azurity Pharmaceuticals
Compare insights from companies similar to Azurity Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Azurity Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Azurity Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Azurity Pharmaceuticals.
Azurity Pharmaceuticals Tech Stack
A closer look at the technologies used by Azurity Pharmaceuticals
See more technologies
Most Recent Scoops
Open Position
Layoffs
Layoffs
Open Position
Open Position
Open Position
Azurity Pharmaceuticals News & Media
Azurity Pharmaceuticals Announces the Availability of ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution, CII
Woburn, MA, April 06, 2026 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals, Inc. announced that ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution is now available in the United States for treating ADHD in adults and pediatric patients 6 years and older. Arynta, a ready-to-use lisdexamfetamine oral solution that may be stored at room temperature between 68°F to 77°F (20°C to 25°C),1 received FDA approval in June 2025.Azurity Pharmaceuticals Announces FerabrightTM (ferumoxytol injection) Now Available in the U.S. for Magnetic Resonance Imaging of the Brain
Ferabright is the first and only iron-based contrast agent for MRI in the brain Ferabright is the first and only iron-based contrast agent for MRI in the brainAzurity Pharmaceuticals Announces ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution, CII
Woburn, MA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals, Inc. announced that ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution will be available mid-2026 for treating ADHD in adults and pediatric patients 6 years and older. Arynta, a ready-to-use lisdexamfetamine oral solution that may be stored at room temperature between 68°F to 77°F (20°C to 25°C),1 received FDA approval in June 2025.ACA Pharma Named Exclusive Distributor for Ferabright™ in Macau, Hong Kong, Singapore, Greater Bay Area & Mainland China
NEW YORK, NY, UNITED STATES, January 14, 2026 /EINPresswire.com/ -- ACA Pharma and Azurity Pharmaceuticals are pleased to announce that they have entered into an exclusive distribution partnership under which ACA Pharma will commercialize Ferabright™ ( …
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Azurity Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Azurity Pharmaceuticals is a privately held biopharmaceutical company focused on developing and delivering innovative, high-quality medicines for underserved patients. With a diverse portfolio across multiple therapeutic areas and dosage forms, the company leverages advanced commercial strategies, data, and digital tools to enhance reach and engage... Read More
